Volume 18, Number 1—January 2012
Dispatch
Early Detection of Pandemic (H1N1) 2009, Bangladesh
, Mustafizur Rahman, Abdullah Al Mamun, Mohammad Sabbir Haider, Rashid Uz Zaman, Polash Chandra Karmakar, Sharifa Nasreen, Syeda Mah-E Muneer, Nusrat Homaira, Doli Rani Goswami, Be-Nazir Ahmed, Mohammad Mushtuq Husain, Khondokar Mahbuba Jamil, Selina Khatun, Mujaddeed Ahmed, Apurba Chakraborty, Alicia Fry, Marc-Alain Widdowson, Joseph S. Bresee, Tasnim Azim, A.S.M. Alamgir, Abdullah Brooks, Mohamed Jahangir Hossain, Alexander Klimov, Mahmudur Rahman, and Stephen P. Luby
Table 2
Clinical description of case-patients infected with pandemic (H1N1) 2009 virus seeking treatment, by surveillance platform, Bangladesh, June 2009–October 2010
| Description of case-patient | Event-based surveillance, n = 182 (%) | Sentinel-site surveillance, n = 527 (%) | Kamalapur community-based surveillance, n = 621 (%) | Mirpur community-based surveillance, n = 41 (%) |
|---|---|---|---|---|
| At high risk for complications from influenza illness | 79 (43) | 331 (63) | 285 (4) | 41 (100) |
| Preexisting conditions* | 54 (30)† | 182 (35) | 22 (3) | 0 |
| Danger signs (i.e., difficulty breathing or shortness of breath) | 50 (27 )† | 230 (44) | 47 (8) | 5 (12) |
| Treated with oseltamivir‡ when treatment indicated† | 4/56 (84) | 7/207 (3) | 81/272 (30) | 1/41 (2) |
| Median days from symptom onset to treatment with oseltamivir | 2 (2–4) | 5 (2–8) | 4 (1–5) | 5 |
| Hospitalization | 29 (16)† | 259 (49) | 0 | 0 |
| Death | 3 (2)† | 25 (5) | 0 | 0 |
*Preexisting conditions among event and sentinel site surveillance case-patients included asthma (71[10%]), chronic obstructive lung disease (31 [4%]), obesity (47 [7%]), immune suppression (20 [3%]), diabetes (12 [2%]), chronic heart disease (10 [1%]), neuromuscular disorders (10 [1%]), liver disease (10 [1%]), and hematologic disorders (8 [1%]), cancer (3 [0.4%]), and pregnancy (3 [0.4%]), while 2 community-based surveillance case-patients had immunosuppression (0.3%), 2 (0.3%) had asthma, and 1 (0.1%) had diabetes.
†Comparison between surveillance sites, Pearson χ2 p<0.0001.
‡Oseltamivir 5 mg 2×/d for 5 days.